|
HY-112582-10mg
|
MedChemexpress LLC
|
N1-Methylpseudouridine [CAS 13860-38-3]
|
|
COVID-19-immunoregulation
|
|
|
HY-112582-100mg
|
MedChemexpress LLC
|
N1-Methylpseudouridine [CAS 13860-38-3]
|
|
COVID-19-immunoregulation
|
|
|
HY-112582-25mg
|
MedChemexpress LLC
|
N1-Methylpseudouridine [CAS 13860-38-3]
|
|
COVID-19-immunoregulation
|
|
|
HY-112582-5mg
|
MedChemexpress LLC
|
N1-Methylpseudouridine [CAS 13860-38-3]
|
|
COVID-19-immunoregulation
|
|
|
HY-112582-50mg
|
MedChemexpress LLC
|
N1-Methylpseudouridine [CAS 13860-38-3]
|
|
COVID-19-immunoregulation
|
|
|
HY-109008-10mg
|
MedChemexpress LLC
|
Nacubactam [CAS 1452458-86-4]
|
|
COVID-19-immunoregulation
|
|
|
HY-109008-100mg
|
MedChemexpress LLC
|
Nacubactam [CAS 1452458-86-4]
|
|
COVID-19-immunoregulation
|
|
|
HY-109008-5mg
|
MedChemexpress LLC
|
Nacubactam [CAS 1452458-86-4]
|
|
COVID-19-immunoregulation
|
|
|
HY-109008-50mg
|
MedChemexpress LLC
|
Nacubactam [CAS 1452458-86-4]
|
|
COVID-19-immunoregulation
|
|
|
HY-109008-1mL
|
MedChemexpress LLC
|
Nacubactam [CAS 1452458-86-4] (10mM in DMSO)
|
|
COVID-19-immunoregulation
|
|
|
HY-P77099-10ug
|
MedChemexpress LLC
|
NCKIPSD, Human (His)
|
|
|
|
|
HY-P77099-5ug
|
MedChemexpress LLC
|
NCKIPSD, Human (His)
|
|
|
|
|
HY-D0845-1mg
|
MedChemexpress LLC
|
Nitrosoglutathione [CAS 57564-91-7]
|
|
|
|
|
HY-D0845-10mg
|
MedChemexpress LLC
|
Nitrosoglutathione [CAS 57564-91-7]
|
|
|
|
|
HY-D0845-100mg
|
MedChemexpress LLC
|
Nitrosoglutathione [CAS 57564-91-7]
|
|
|
|
|
HY-D0845-5mg
|
MedChemexpress LLC
|
Nitrosoglutathione [CAS 57564-91-7]
|
|
|
|
|
HY-D0845-50mg
|
MedChemexpress LLC
|
Nitrosoglutathione [CAS 57564-91-7]
|
|
|
|
|
HY-122331-100mg
|
MedChemexpress LLC
|
Norbormide [CAS 991-42-4]
|
|
|
|
|
HY-P71177-10ug
|
MedChemexpress LLC
|
Nucleobindin-2, Human
|
|
|
|
|
HY-P71177-50ug
|
MedChemexpress LLC
|
Nucleobindin-2, Human
|
|
|
|
|
HY-110374-1mg
|
MedChemexpress LLC
|
NVS-CECR2-1 [CAS 1992047-61-6]
|
|
Cancer-programmed cell death
|
|
|
HY-110374-10mg
|
MedChemexpress LLC
|
NVS-CECR2-1 [CAS 1992047-61-6]
|
|
Cancer-programmed cell death
|
|
|
HY-110374-100mg
|
MedChemexpress LLC
|
NVS-CECR2-1 [CAS 1992047-61-6]
|
|
Cancer-programmed cell death
|
|
|
HY-110374-25mg
|
MedChemexpress LLC
|
NVS-CECR2-1 [CAS 1992047-61-6]
|
|
Cancer-programmed cell death
|
|
|
HY-110374-5mg
|
MedChemexpress LLC
|
NVS-CECR2-1 [CAS 1992047-61-6]
|
|
Cancer-programmed cell death
|
|
